Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367523 | 0.68 | EGFR (0.32) | EGFR | |
| SCHEMBL127479 | 0.61 | EGFR (0.50) | EGFR | |
| SCHEMBL6805575 | 0.60 | — | — | |
| SCHEMBL6235782 | 0.59 | — | — | |
| SCHEMBL28003243 | 0.59 | EGFR (0.48) | EGFR | |
| SCHEMBL207434 | 0.57 | — | — | |
| SCHEMBL360968 | 0.57 | — | — | |
| SCHEMBL29450178 | 0.55 | — | — | |
| SCHEMBL63453 | 0.55 | — | — | |
| SCHEMBL28276523 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974782-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-9422242-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150080394-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | COLUMBIA UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2379076-B1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8697875-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2578588-A1 | NOVEL 1,4-DIAZEPAM PDE-5 INHIBITOR DERIVATIVES | World-Trade Import-Export Wtie, AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-20120076732-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-29 | — | — | US | disclosed |
| EP-2379076-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
| US-6723719-B1 | DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS | PFIZER INC | 2004-04-20 | — | — | US | disclosed |
| EP-1372656-A1 | PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| EP-1123296-B1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020198223-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002074312-A1 | PYRAZOLO`4,3-D.PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| US-6333330-B1 | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-12-25 | — | — | US | disclosed |
| EP-1123296-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000024745-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198223-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | EGFR 4834/4885 |
| US-20120076732-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | EGFR 4802/4885 |
| US-20150080394-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | EGFR 4802/4885 |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | EGFR 4802/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | EGFR 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.